# TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors

> **NCT06500091** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 54 (estimated)

## Conditions studied

- Soft Tissue Sarcoma
- Melanoma

## Interventions

- **DRUG:** TQB2916 injection + doxorubicin hydrochloride for injection
- **DRUG:** TQB2916 injection+penpulimab injection

## Key facts

- **NCT ID:** NCT06500091
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07
- **Primary completion:** 2026-06
- **Final completion:** 2026-12
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2024-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06500091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06500091, "TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06500091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*